Neurocrine Biosciences Inc

NBIX remains in a Stage 2 advance within a healthy long-term uptrend. The medium-term tradable bias is bullish, and the recent pullback into the rising 9- and 21-day EMA zone has presented a favorable buy setup. Short-term momentum signals a potential bounce from support, aligning with our Growth at Reasonable Price strategy to engage on structural pullbacks.

• ↑Q1 2026 product sales jumped 44% YoY, surpassing $800M
• ↑Ingresa revenue hit $657M in Q1, fueled by new patient additions
• ↓Negative book-to-price and dividend yield factors suggest valuation premium